| Literature DB >> 35370742 |
Masakazu Kotoda1, Toru Matsuoka1, Keiichi Wada1, Selwyn Jayakar2, Hirofumi Ino1, Koji Kawago3, Yasutomo Kumakura1.
Abstract
Local anesthetics with long-lasting effects and selectivity for nociceptors have been sought over the past decades. In this study, we investigated whether amiodarone, a multiple channel blocker, provides long-lasting local anesthesia and whether adding a TRPV1 channel activator selectively prolongs sensory anesthetic effects without prolonging motor blockade. Additionally, we examined whether amiodarone provides long-lasting analgesic effects against inflammatory pain without TRPV1 channel activator co-administration. In the sciatic nerve block model, 32 adult C57BL/6J mice received either bupivacaine, amiodarone with or without capsaicin (a TRPV1 agonist), or vehicle via peri-sciatic nerve injection. Sensory and motor blockade were assessed either by pinprick and toe spread tests, respectively. In another set of 16 mice, inflammatory pain was induced in the hind paw by zymosan injection, followed by administration of either amiodarone or vehicle. Mechanical and thermal sensitivity and paw thickness were assessed using the von Frey and Hargreaves tests, respectively. The possible cardiovascular and neurological side effects of local amiodarone injection were assessed in another set of 12 mice. In the sciatic nerve block model, amiodarone produced robust anesthesia, and the co-administration of TRPV1 agonist capsaicin prolonged the duration of sensory blockade, but not that of motor blockade [complete sensory block duration: 195.0 ± 9.8 min vs. 28.8 ± 1.3 min, F (2, 21) = 317.6, p < 0.01, complete motor block duration: 27.5 ± 1.6 min vs. 21.3 ± 2.3 min, F (2, 22) = 11.1, p = 0.0695]. In the zymosan-induced inflammatory pain model, low-dose amiodarone was effective in reversing the mechanical and thermal hypersensitivity not requiring capsaicin co-administration [50% withdrawal threshold at 8 h (g): 0.85 ± 0.09 vs. 0.25 ± 0.08, p < 0.01, withdrawal latency at 4 h (s) 8.5 ± 0.5 vs. 5.7 ± 1.4, p < 0.05]. Low-dose amiodarone did not affect zymosan-induced paw inflammation. Local amiodarone did not cause cardiovascular or central nervous system side effects. Amiodarone may have the potential to be a long-acting and nociceptor-selective local anesthetic and analgesic method acting over open-state large-pore channels.Entities:
Keywords: TRPV1 channel; amiodarone; anesthetics; inflammation; pain
Year: 2022 PMID: 35370742 PMCID: PMC8971742 DOI: 10.3389/fphar.2022.872477
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Sensory and motor blockade after peri-sciatic nerve injection using the pinprick and toe spread tests (n = 8 each). (A) Pinprick response rate. (B) Duration of complete sensory block defined as the pinprick response rate of 0%. (C) Toe spread score. (D) Duration of complete motor block defined as the toe spread score of 0. AMD: amiodarone; Cap: capsaicin *p < 0.05 vs. bupivacaine; **p < 0.01 vs. bupivacaine ††p < 0.01 vs. AMD.
FIGURE 2Mechanical and thermal sensitivity and paw thickness after zymosan injection. (A) 50% withdrawal threshold values based on the von Frey test with the up-down method. (B) Thermal withdrawal latency assessed by the Hargreaves test. (C) Paw thickness after zymosan injection AMD: amiodarone *p < 0.05 vs. vehicle; **p < 0.01 vs. vehicle.
FIGURE 3Assessment of cardiovascular and neurological effects by local amiodarone. (A) Heart rate measured using three-probe electrogram. (B) Noninvasive mean arterial blood pressure measured using the tail-cuff method. (C) Spontaneous activity after zymosan injection assessed using the open-field test. The number of lines crossed with all paws during a 5-min period was counted. AMD: amiodarone.